The Lustgarten Foundation takes a bold approach to funding research. Our unique funding model sets us apart from other organizations and enables us to lead the field of pancreatic cancer research and move studies forward faster. The only way we are going to conquer this disease is with significant grants awarded to the brightest scientific minds.
Break Through Cancer
The Lustgarten-funded Conquering KRAS in Pancreatic Cancer Team integrates clinical and laboratory approaches to understand why patients do or do not respond to the new therapies using breakthrough single-cell technologies to deeply investigate tumor biology. The team also develops pharmaceutical partnerships to accelerate the translation of new KRAS inhibitors into effective drugs for pancreatic cancer.
Clinical Translational Research Program
The program identifies and funds innovative, multi-institutional translational research projects that will significantly impact early diagnosis, increase surgical intervention, improve therapies, identify personalized medicine approaches and ultimately find a cure for pancreatic cancer.
Research Investigator Program
This program funds talented scientists with historical accomplishments in cancer research who are now focusing their efforts on pancreatic cancer. Scientists are awarded three-year grants for projects that are focused on the science underlying pancreatic cancer to achieve early diagnosis and improved therapies.
Pancreatic Cancer Collective
This joint initiative of the Lustgarten Foundation and Stand Up To Cancer is an exciting initiative to improve patient outcomes. Together, we are creating a dynamic and fluid network engaging medical institutions, researchers and companies. In addition to working with the leaders in pancreatic cancer research, we are funding new centers and bringing new talent to the field with the goal of accelerating research for patients who desperately need better treatments.